WOODBRIDGE, ON, April 15, 2015 /PRNewswire/ - Pivotal
Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the
"Company"), a specialty pharmaceutical company with a focus on
Omega-3 therapies for cardiovascular disease and overall health,
announced today that it has entered into a Memorandum of
Understanding with Korea Animal Medical Science Institute (KAMSI)
and its newly created affiliate for the exclusive sales and
distribution of the BeneFishial™ family of
products. The BeneFishial™ family of
products consists of the following six products: (i)
BeneFishial™ for overall health and
well being, (ii) BeneFishial™ for
cardiovascular health, (iii) BeneFishial™
for prenatal health, (iv) BeneFishial™ for
toddler's health, (v) BeneFishial™ for
child's health and (vi) BeneFishial™ for
pet's health (veterinary application).
The distribution agreement focuses on Pivotal's
BeneFishial™ line of products for the
nutraceutical and veterinary markets in Korea and the veterinary
market in Japan. The agreement
also provides for an upfront payment and guaranteed minimum annual
sales targets to be achieved.
"Pivotal is an attractive partner offering a large spectrum of
patented formulations each delivering convincing health benefits to
multiple user groups in Korea and Japan," said Mr. Cheolseung Peck, CEO of
KAMSI's affiliate.
"We are delighted to partner with Korea's leading pre-clinical
and regulatory contract research organization that will lead the
way for Pivotal into this highly professional and competitive
market place. Their unique experience in registering complex
products including safety and reimbursement together with their
proven international and U.S. experienced executive team provides a
unique basis for a sustainably successful launch of our products in
these important Asian markets that are Korea and Japan," said Mr. Eugene Bortoluzzi, Pivotal's CEO and CFO.
About BeneFishial™
BeneFishial™ was created as the
cornerstone of our new nutraceutical product line, which will
include prenatal, children, heart and animal health orientated
products. BeneFishial™ is designed to be
sold as a nutraceutical in the OTC direct to retail or direct to
consumer markets in both the U.S. and in Canada. BeneFishial™
contains the highest content of Omega-3 fatty acids of any other
OTC product on the market. It is specifically formulated to give
the highest purity, highest anti-inflammatory properties and the
best therapeutic effect for a healthy body and mind. It contains
the optimal purity, ratio and dose of Omega-3 and is a simple
solution to a number of health risk factors.
About Pivotal Therapeutics Inc.
Pivotal Therapeutics is a publicly traded (OTCQX:PVTTF;
CSE:PVO), specialty pharmaceutical company with a focus on
cardiovascular disease and overall health. Pivotal Therapeutics'
lead product VASCAZEN® is a prescription only
medical food formulated to meet the dietary Omega-3 deficient needs
of patients with cardiovascular disease through elevating
Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to
levels associated with reduced risk of cardiovascular
complications. OMAZEN® is a pharmaceutical
grade Omega-3 providing over 90% pure Omega-3 in each capsule for
the maintenance of good health. OMAZEN® is a
patented product available for sale and distribution in
Canada. BeneFishial™ is the
first product in Pivotal's new nutraceutical product line, which
has been specifically designed to be sold in the OTC direct to
retail or direct to consumer markets.
About KAMSI
KAMSI, founded in 2012, is a privately owned, science and
technology driven, fully integrated and globally active Korean pre-
and non-clinical contract research organization. Its focus lies on
the development and application of an extensive range of disease
area specific proprietary platform technologies used in combination
with in-house pharmacokinetic, toxicological and pathological
expertise made available to the pharmaceutical and biotechnology
industries and tailored to Korean and international regulatory
requirements.
Disclosure Notice
The information contained in this document is as April 15, 2015. This press release contains
forward-looking statements. Such forward-looking statements are
subject to a number of risks, assumptions and uncertainties that
could cause Pivotal's actual results to differ materially from
those projected in such forward-looking statements. These
statements can be identified by the use of words such as "will",
"anticipate", "estimate", "expect", "project", "forecast",
"intend", "plan", "believe", "project", "potential", and similar
expressions with any discussion of future operating or financial
performance or events. In particular, factors that could cause
actual results to differ materially from those in forward looking
statements include the following: Pivotal's inability to obtain
additional financing on acceptable terms; growth in costs and
expenses; inability to compete with others who provide comparable
products; risk that the Company's products will not gain widespread
market acceptance; risks relating to the Company's ability to
maintain its CSE listing. Forward-looking statements speak only as
of the date made and are not guarantees of future performance.
The Company undertakes no obligation to publicly update or
revise any forward-looking statements contained in this document as
a result of new information or future events or developments. The
CSE has not reviewed and does not accept responsibility for the
adequacy or accuracy of this information.
SOURCE Pivotal Therapeutics Inc.